BR112022013628A2 - Métodos para tratar doenças inflamatórias intestinais com antagonistas de integrina alpha-4 beta-7 - Google Patents
Métodos para tratar doenças inflamatórias intestinais com antagonistas de integrina alpha-4 beta-7Info
- Publication number
- BR112022013628A2 BR112022013628A2 BR112022013628A BR112022013628A BR112022013628A2 BR 112022013628 A2 BR112022013628 A2 BR 112022013628A2 BR 112022013628 A BR112022013628 A BR 112022013628A BR 112022013628 A BR112022013628 A BR 112022013628A BR 112022013628 A2 BR112022013628 A2 BR 112022013628A2
- Authority
- BR
- Brazil
- Prior art keywords
- inflammatory bowel
- methods
- bowel diseases
- treatment
- antagonists
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062959854P | 2020-01-10 | 2020-01-10 | |
| PCT/US2021/012842 WO2021142373A1 (en) | 2020-01-10 | 2021-01-08 | METHODS FOR TREATING INFLAMMATORY BOWEL DISEASES WITH α4β7 INTEGRIN ANTAGONISTS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022013628A2 true BR112022013628A2 (pt) | 2022-11-22 |
Family
ID=76788328
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022013628A BR112022013628A2 (pt) | 2020-01-10 | 2021-01-08 | Métodos para tratar doenças inflamatórias intestinais com antagonistas de integrina alpha-4 beta-7 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230063321A1 (enExample) |
| EP (1) | EP4093421A4 (enExample) |
| JP (2) | JP7744910B2 (enExample) |
| KR (1) | KR20220125268A (enExample) |
| AU (1) | AU2021205415B2 (enExample) |
| BR (1) | BR112022013628A2 (enExample) |
| CA (1) | CA3166637A1 (enExample) |
| IL (1) | IL294580A (enExample) |
| MX (1) | MX2022008486A (enExample) |
| PH (1) | PH12022551651A1 (enExample) |
| WO (1) | WO2021142373A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4091624A1 (en) | 2013-03-15 | 2022-11-23 | Protagonist Therapeutics, Inc. | Hepcidin analogues and uses thereof |
| CA2949215C (en) | 2014-05-16 | 2023-03-14 | Protagonist Therapeutics, Inc. | .alpha.4.beta.7 integrin thioether peptide antagonists |
| SG10201810154WA (en) | 2014-07-17 | 2018-12-28 | Protagonist Therapeutics Inc | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases |
| WO2018022937A1 (en) | 2016-07-27 | 2018-02-01 | Protagonist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 and their use to treat inflammatory diseases |
| WO2019157268A1 (en) | 2018-02-08 | 2019-08-15 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
| CA3104418A1 (en) | 2018-07-12 | 2020-01-16 | Protagonist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| MX2022008740A (es) | 2020-01-15 | 2022-09-23 | Janssen Biotech Inc | Peptidos inhibidores del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias. |
| SMT202500254T1 (it) | 2020-01-15 | 2025-09-12 | Janssen Biotech Inc | Inibitori peptidici del recettore dell'interleuchina-23 e loro uso per trattare malattie infiammatorie |
| AU2021383828A1 (en) | 2020-11-20 | 2023-07-06 | Janssen Pharmaceutica Nv | Compositions of peptide inhibitors of interleukin-23 receptor |
| KR20240034224A (ko) | 2021-07-14 | 2024-03-13 | 얀센 바이오테크 인코포레이티드 | 인터류킨-23 수용체의 지질화된 펩티드 억제제 |
| KR20250084325A (ko) * | 2023-12-01 | 2025-06-11 | 주식회사 쓰리빅스 | 염증성 장질환 예방 또는 치료용 약학 조성물 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2013011130A (es) * | 2011-03-31 | 2013-10-30 | Genentech Inc | Metodos de administracion de antagonistas de integrina beta7. |
| WO2013078375A2 (en) * | 2011-11-23 | 2013-05-30 | Amgen Inc. | Administration of alpha4beta7 hetero-dimer-specific antibody |
| US9273093B2 (en) * | 2012-10-11 | 2016-03-01 | Protagonist Therapeutics, Inc. | α4β7 peptide dimer antagonists |
| CA2949215C (en) * | 2014-05-16 | 2023-03-14 | Protagonist Therapeutics, Inc. | .alpha.4.beta.7 integrin thioether peptide antagonists |
| JP2017535527A (ja) * | 2014-10-01 | 2017-11-30 | プロタゴニスト セラピューティクス， インコーポレイテッド | 新規のα４β７ペプチド単量体及び二量体拮抗薬 |
| KR20200015540A (ko) * | 2017-05-10 | 2020-02-12 | 인사이클 세라퓨틱스, 인코포레이티드 | α4β7 인테그린을 타겟팅하는 호모데틱 사이클릭 펩타이드 |
-
2021
- 2021-01-08 EP EP21738981.6A patent/EP4093421A4/en active Pending
- 2021-01-08 JP JP2022542360A patent/JP7744910B2/ja active Active
- 2021-01-08 BR BR112022013628A patent/BR112022013628A2/pt not_active Application Discontinuation
- 2021-01-08 MX MX2022008486A patent/MX2022008486A/es unknown
- 2021-01-08 CA CA3166637A patent/CA3166637A1/en active Pending
- 2021-01-08 WO PCT/US2021/012842 patent/WO2021142373A1/en not_active Ceased
- 2021-01-08 PH PH1/2022/551651A patent/PH12022551651A1/en unknown
- 2021-01-08 AU AU2021205415A patent/AU2021205415B2/en active Active
- 2021-01-08 US US17/788,179 patent/US20230063321A1/en active Pending
- 2021-01-08 KR KR1020227025943A patent/KR20220125268A/ko not_active Withdrawn
-
2022
- 2022-07-07 IL IL294580A patent/IL294580A/en unknown
-
2025
- 2025-09-12 JP JP2025151922A patent/JP2025186365A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021142373A1 (en) | 2021-07-15 |
| JP2023509790A (ja) | 2023-03-09 |
| JP7744910B2 (ja) | 2025-09-26 |
| AU2021205415A8 (en) | 2023-08-10 |
| IL294580A (en) | 2022-09-01 |
| US20230063321A1 (en) | 2023-03-02 |
| AU2021205415B2 (en) | 2026-06-04 |
| KR20220125268A (ko) | 2022-09-14 |
| PH12022551651A1 (en) | 2023-11-20 |
| CA3166637A1 (en) | 2021-07-15 |
| EP4093421A1 (en) | 2022-11-30 |
| MX2022008486A (es) | 2022-10-13 |
| CN115038457A (zh) | 2022-09-09 |
| JP2025186365A (ja) | 2025-12-23 |
| EP4093421A4 (en) | 2024-01-10 |
| AU2021205415A1 (en) | 2022-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12022551651A1 (en) | METHODS FOR TREATING INFLAMMATORY BOWEL DISEASES WITH a4Ã7 INTEGRIN ANTAGONISTS | |
| Yazici et al. | A novel Wnt pathway inhibitor, SM04690, for the treatment of moderate to severe osteoarthritis of the knee: results of a 24-week, randomized, controlled, phase 1 study | |
| Karsdal et al. | Treatment of symptomatic knee osteoarthritis with oral salmon calcitonin: results from two phase 3 trials | |
| JP2022037132A (ja) | 筋萎縮性側索硬化症患者の下位集団の治療のためのマシチニブの使用 | |
| EA202193190A1 (ru) | Композиция, включающая придопидин и его аналог, для лечения болезни гентингтона и ее симптомов | |
| Distler et al. | RISE-SSc: Riociguat in diffuse cutaneous systemic sclerosis | |
| BR112022015151A2 (pt) | Método para reduzir ou prevenir progressão de um tumor ou tratar câncer, e, composição | |
| WO2016030334A2 (en) | Methods, agents and compositions for treatment of inflammatory conditions | |
| Premkumar et al. | Venetoclax in immunoglobulin light chain amyloidosis: is this the beginning or the end? | |
| MX2023012455A (es) | Golexanolona para usarse en el tratamiento de la fatiga o deterioro cognitivo en pacientes con enfermedad hepatica. | |
| Bali et al. | Cyclosporine reduces sclerosis in morphea: a retrospective study in 12 patients and a literature review | |
| BR112022008095A2 (pt) | Métodos e composições para o tratamento da síndrome de rett | |
| CA3255735A1 (en) | NEW TREATMENT FOR FACIO-SCAPULO-HUMERAL MUSCULAR DYSTROPHY (FSHD) | |
| WO2023141176A3 (en) | Neutralizing antibodies and antigen-binding fragments thereof against omicron and other coronavirus variants, and methods of making and using the same | |
| WO2020211772A1 (en) | Purmorphamine as a small compound positive allosteric modulator of secretin receptor for the treatment of hypertension | |
| Cho et al. | Scleroderma-like manifestation in a patient with primary systemic amyloidosis: response to high-dose intravenous immunoglobulin and plasma exchange | |
| WO2022004788A1 (ja) | 代謝異常を伴う疾患又は症候群における筋力低下症状の改善剤又は予防剤 | |
| BR112022017942A2 (pt) | Composição farmacêutica para prevenção ou tratamento de diabetes e doenças metabólicas associadas à mesma | |
| RU2774830C1 (ru) | Способ ранней диагностики воспаления плечевого сустава у собак | |
| Tatara et al. | 7. Novel and current approaches to dietary and non-dietary bone metabolism regulation | |
| JOP20200282A1 (ar) | مركب جديد ينطوي على نشاط مثبط للإنتيروببتيداز | |
| Delforge et al. | The LocoMMotion Study (MMY4001): A Prospective, Multinational Study of Real-Life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including PI, IMiD, and CD38 Monoclonal Antibody Treatment and Documented Disease Progression | |
| Bakı et al. | Applicatıon of femoral+ sciatic block in high risk patients: Two cases | |
| IT201800006455A1 (it) | Nuovo utilizzo degli inibitori della monoammino ossidasi B | |
| Chou et al. | Rabbit spinal cord ischemia model for the development of neuroprotective treatments |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |